euro adhoc: Marseille-Kliniken AG / Financial Figures/Balance Sheet / - Turnover increase in first half-year 2008/2009 to EUR 116.8 million - Both segments generating positive contributions to income - Positive development in occupancy expected for second half-year 2008/2009 (E)

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

10.02.2009

Berlin, 10 February 2009. Marseille-Kliniken AG was able to continue to increase
operating turnover in the first half of the current financial year (1 July 2008
- 31 December 2008) by 4.2 % to EUR 116.8 million (previous year: EUR 112.1
million). As expected Group net income after minority interest fell from EUR
12.1 million to EUR 1.0 million as a result of one-time effects (EUR 11.9
million) incurred in the previous year. This translates into earnings per share
of EUR 0.08 compared to EUR 1.00 in the previous year. EBIT/IFRS amounted to EUR
4.2 million as planned after EUR 12.5 million including one-time effects in the
previous year. EBITDAR/IFRS reached EUR 31.7 million, previously EUR 37.0
million. Equity amounted to EUR 80.8 million after EUR 84.5 million in the
previous year. The equity ratio increased to 35.5 % (previous year: 33.8 %),
while net debt dropped slightly from EUR 66.4 million to EUR 65.9 million.

The drop in results according to German Commercial Code can be mainly attributed
to an extraordinary gain in the previous year, which back then consisted of EUR
4.9 million from the corporation tax reform 2008 as well as EUR 8.1 million from
the sale of a real estate asset. These and similar one-time effects were not
recorded in the period under review.

Adjusted earnings according to DVFA/SG (IFRS) reached EUR 6.6 million in the
previous period and dropped slightly in the period under review to EUR 6.2
million. Per share this amounts to EUR 0.51 (previous year: EUR 0.54). This was
mainly attributable to increased costs for securing heating oil prices, higher
expenses for personnel recruitment as well as audit costs. Adjusted EBITDAR
increased from EUR 31.5 million in the previous year to EUR 32.7 million, while
adjusted EBIT came in at EUR 9.0 million in the period under review after EUR
10.0 in the previous year. At group level occupancy continued at high levels,
with capacity being increased by 200 beds. Occupancy for the 9,100 beds reached
92.4 % (previous year: 92.5 % at 8,899 beds). Adjustments are mainly due to
start up expenses for seven Care facilities with currently 781 beds (8.6 % of
capacity) as well as four facilities, which are not yet operational, and a
medical centre in the Rehabilitation segment only taken over in mid 2008.

Capacity in the Care segment increased from 7,616 beds to 7,771 beds in the
period under review. Turnover in the segments increased from EUR 86.8 million in
the previous year to EUR 90.5 million. Earnings according to DVFA/SG (IFRS)
reached EUR 5.1 million (previous year: EUR 6.6 million) were negatively
impacted by expenses for securing heating oil prices, personnel recruitment
costs and audit costs. Including the Düsseldorf and Potsdam facilities occupancy
in Care came in at 92.7 % after 93.6 % in the previous year.

The segment Rehabilitation developed very positively. In the period under review
its capacity increased slightly to 1,329 beds (previous year: 1,283 beds) on the
back of commissioning more beds in Schömberg. Turnover generated increased from
EUR 25.4 million in the previous year to EUR 26.3 million. Earnings according to
DVFA/SG (IFRS) improved to EUR 1.1 million after previously breaking-even.
Restructuring measures continue to be successful and occupancy at the segment
improved from 89.1 % to 92.5 %.

As a result, Marseille-Kliniken AG continues to be heading towards the set
targets. The company is on a sound track which is almost untouched by the
currently difficult economic situation. This will allow further sustained growth
and at the same time means that the company can make reliable plans for the
development of its business. We are expecting to see improvements in occupancy
levels in Care, while Rehabilitation will sustain its high occupancy levels. In
Q3 Marseille-Kliniken will continue to benefit from falling start-up expenses,
which will have a positive impact on future quarterly results. Tapping
cost-saving potential in the current financial year is to bring about a further
improvement in profitability. Against this backdrop, the Management Board is
maintaining its growth forecast of a 6.5 % average for the current and the next
financial year as well as EBIT return of at least 7 % for the current financial
year.

For more detailed information, please visit the website
www.marseille-kliniken.com to read the half-year report.

End of ad hoc release

Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin
Germany
Tel.: +49 30 / 246 32-400
Fax: +49 30 / 246 32-401
www.marseille-kliniken.com

Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49 40 / 320 279 10
Fax: +49 40 / 320 279 114
www.hillermann-consulting.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

emitter: Marseille-Kliniken AG
Alte Jakobstraße 79/80
D-10709 Berlin
phone: +49 (0)30 246 32-400
FAX: +49 (0)30 246 32-401
mail: [email protected]
WWW: http://www.marseille-kliniken.de
sector: Pharmaceuticals
ISIN: DE0007783003
indexes: CDAX, Classic All Share, Prime All Share
stockmarkets: regulated dealing/prime standard: Börse Frankfurt, free trade:
Börse Berlin, Börse Stuttgart, Börse Düsseldorf, regulated
dealing: Börse Hamburg
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | OTB

print